|Bid||194.17 x 100|
|Ask||194.24 x 100|
|Day's Range||191.46 - 194.51|
|52 Week Range||132.92 - 216.01|
|PE Ratio (TTM)||48.19|
|Earnings Date||Oct 24, 2017 - Oct 30, 2017|
|Dividend & Yield||1.12 (0.60%)|
|1y Target Est||214.50|
We look forward to a solid customer adoption of Medtronic's (MDT) Intellis platform, considering the vast and expanding market for chronic pain management.
The market is upbeat about Abbott (ABT) acquiring the national reimbursement for FreeStyleLibre glucose monitoring system in the United Kingdom. Several product launches also add value.
After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).